cemiplimab,fianlimab
sanofi,regeneron
[]
these results are quite remarkable, waiting for the phase ii/iii trial. #smr2022 
Medical oncologist, @lemelbaum institute for immuno-oncology. Treating patients with #Melanoma, interested in #Immunotherapy and clinical trials